Medipharm Labs Corp's stock surged by 7.69% in the last trading session, marking a notable gain for investors.
On the TSX, Medipharm Labs Corp (LABS.TO) saw its stock price rise to CA$0.07. This increase comes alongside positive developments in the company's operations and market position.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Medipharm Labs Corp
LABS.TO
LABS.TO
Medipharm Labs Corp
WealthAwesomeMarket cap
$32.93M
52W high
$0.10
52W low
$0.06
1W change
+6.67%
Beta
0.92
Analyst Price Targets
Based on analyst covering LABS
Wall Street analysts forecast LABS stock price to rise 25.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.10
+25.0% Upside
Current Price
C$0.08
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LABS's historical volatility
30-Day Vol
86.5%
Annualized
90-Day Vol
84.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.10
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.08 | C$0.06 โ C$0.11 |
| 60 trading days | C$0.09 | C$0.06 โ C$0.14 |
| 90 trading days | C$0.10 | C$0.06 โ C$0.16 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Medipharm Labs is making strategic moves that could strengthen its market presence, especially in international markets, which may lead to future growth.
Medipharm Labs Corp's stock jumps 7.69% in one day
With a market cap of CA$29.74 million, the company's stock performance reflects investor optimism following its recent operational advancements.
Bull case
The company reported an 8% annual revenue increase and has successfully entered the European medical cannabis market. This expansion could boost revenue further.
Bear case
Despite the recent gains, Medipharm Labs is still operating at a loss. Ongoing market volatility in the cannabis sector could affect future performance.
Recent Performance Highlights
Medipharm Labs Corp's stock price closed at CA$0.07, reflecting a strong performance with a 7.69% increase in a single trading day. This gain is particularly noteworthy considering the company's recent strategic initiatives aimed at expanding its international footprint.
Strategic Developments
The company has made headlines by completing its first shipment to France, marking its entry into the European medical cannabis market. Additionally, an 8% annual revenue increase to CA$45.1 million highlights its growing international medical cannabis revenue, which now makes up over 50% of total revenue.
Market Outlook
While the recent gains are promising, investors should remain cautious. Medipharm Labs continues to navigate a challenging market environment, and its current profit margin is negative. Future performance will depend on the company's ability to capitalize on its recent expansions and manage operational costs effectively.
Advertisement
